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Introduction {#sec1}
============

Chromosome 17q21 represents an interesting genomic locus featuring an ∼1.3--1.6 Mb region of linkage disequilibrium (LD) encompassing the microtubule-associated protein tau (*MAPT*) gene, including genetic variants associated with several neurodegenerative disorders. The LD surrounding *MAPT* is due to a 900 kb chromosomal inversion proposed to originate from non-allelic homologous recombination between long coding repeats flanking the region ([@bib7]), giving rise to two correspondingly large haplotype families called H1 and H2. The *MAPT* gene is of central importance to a number of neurodegenerative diseases. Strong association of *MAPT* H1 haplotype variants has been shown with progressive supranuclear palsy (PSP) ([@bib16]), corticobasal degeneration (CBD) ([@bib20]), and Parkinson\'s disease (PD) ([@bib25]).

The *MAPT* gene is characterized by diversity at the transcript and protein level. The gene expresses six transcripts through the alternative splicing of exons 2, 3, and 10 resulting in six major tau protein isoforms in the adult CNS ([@bib2], [@bib13]). Splicing of exons 2 and 3 yields proteins with 0, 1, or 2 N-terminal inserts (0N, 1N, and 2N tau). Exclusion or inclusion of exon 10 alters the number of microtubule binding repeats to give three or four microtubule binding repeats (3R or 4R tau). Expression of tau protein isoforms shows brain region specificity ([@bib5], [@bib23], [@bib34]) and is regulated during development, with roles in establishing and maintaining neuronal morphology. Importantly, tau proteins have been shown to aggregate in those brain regions that degenerate in a number of diseases, collectively referred to as tauopathies. Tauopathies show differing aggregation compositions of tau protein, with principally 4R tau aggregating in PSP, CBD, and frontotemporal dementia with Parkinsonism associated with chromosome 17 (FTDP-17) ([@bib3], [@bib4]); 3R tau proteins aggregating in Pick\'s disease ([@bib9]); and both 3R and 4R tau aggregating in Alzheimer\'s disease ([@bib28], [@bib37]). Despite having a strong genetic association with *MAPT*, PD does not typically give rise to tau tangle pathologies.

While *MAPT* coding and splice site mutations have been shown to be sufficient to cause FTDP-17, the *MAPT* haplotype variants do not encode protein changes that could underlie the genetic association. We and others have previously studied haplotype effects on gene expression at the *MAPT* locus ([@bib5], [@bib6], [@bib22], [@bib23], [@bib34]). Our studies have shown that the H2 haplotype expresses twice as much exon 2+3+ *MAPT* transcript as H1 ([@bib6]), a finding that has been replicated in a large postmortem brain series ([@bib34]). In addition, we showed that the *MAPT* H1 haplotype expresses 40% more exon 10+(4R) *MAPT* transcript than H2 ([@bib5]), and this difference in exon 10+ transcript expression was greater in the globus pallidus than in the frontal cortex, demonstrating a mechanistic link between the regulation of *MAPT* gene expression by disease-associated polymorphisms and the regional vulnerability exhibited in PSP, a 4R-tauopathy. A previous report has found an increase in the ratio of 4R:3R *MAPT* transcripts in PD brains ([@bib33]), potentially suggesting a shared mechanism of disease.

Induced pluripotent stem cell (iPSC)-derived neuronal cultures provide a powerful and tractable human neuronal model generated directly from individuals with disease, or harboring specific genetic variants. A major advantage of iPSC-derived neuronal cultures is the use in experimental studies of a key cell type of interest, enabling experimental analysis in living human neurons in a manner not attainable using postmortem tissues ([@bib12], [@bib14]). Here, we differentiated dopaminergic neuronal cultures from iPSC lines heterozygous for the *MAPT* H1/H2 haplotypes to assess the effect of *MAPT* haplotype on gene expression and the role of tau protein isoforms in dopamine neurons preferentially vulnerable to degeneration in PD. iPSC-derived dopaminergic neuronal cultures express all six adult tau isoforms, approaching adult levels of expression of exon 3+ and exon 10+ transcripts after 6 months of maturation. This model was shown to be suitable to study both common genetic variations, displaying significant haplotype-specific differences in *MAPT* expression and splicing, as well as being able to characterize the effects of a rare genetic polymorphism on splicing. Finally, we perturbed the expression of both total and 4R tau in iPSC-derived dopamine neurons to demonstrate that tau isoforms regulate axonal transport velocity, linking genetic variation, gene expression, and splicing with neuronal function.

Results {#sec2}
=======

Establishment of Human Dopaminergic Neuronal Cultures that Express Adult Tau Isoforms {#sec2.1}
-------------------------------------------------------------------------------------

To study the relationship between genetic variation at the *MAPT* locus and PD we used human iPSCs to generate dopamine neurons from individuals carrying specific genotypes of interest. As any effect of underlying genetic polymorphic variation on gene expression and splicing is independent of disease status, we chose to use control individuals of known genotype for this study. In addition, by using individuals heterozygous for *MAPT* H1/H2, we are able to assay expression from both haplotypes in one culture controlling for confounding factors such as different genetic backgrounds, culture conditions, or environmental factors. Fifty-eight healthy controls from the Oxford Parkinson\'s Disease Center Discovery Cohort were screened to identify individuals heterozygous for the *MAPT* H1 and H2 alleles. Of the 58 individuals genotyped, 38% were the desired H1/H2 genotype, 53% were H1/H1, and 9% were H2/H2. Fibroblasts from H1/H2 individuals were reprogrammed to generate iPSC clones, some of which have been described previously ([@bib8], [@bib14], [@bib27]) (see also [Table S1](#mmc1){ref-type="supplementary-material"}). Characterization of the new iPSC clones is presented in [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}. In total, eight iPSC clones made from three H1/H2 individuals were selected for use in this study ([Figure 1](#fig1){ref-type="fig"}A, see also [Table S1](#mmc1){ref-type="supplementary-material"}).Figure 1Differentiation of Induced Pluripotent Stem Cells with *MAPT* H1/H2 Genotype into Dopaminergic Neuronal Cultures(A) Genotyping PCR distinguishes the 238 bp indel in *MAPT* intron 9, showing the presence of both the H1 and H2 alleles in all eight iPSC clones. Clones are identified by the number of the individual (1--3) then by the clone generated from reprogramming of the fibroblasts of that individual (A--C).(B) Western blots showing iPSC differentiation into dopamine neuronal cultures. Neuronal marker β3-tubulin (TUJ1) (expressed by DIV20) and tyrosine hydroxylase (TH) are shown at DIV190. Samples from two differentiations are identified by a "1" or "2" suffix.(C) Efficiency of dopaminergic differentiation was quantified from at least two clones per individual. Individuals differentiated with similar efficiencies into neurons determined by TUJ1/DAPI. The proportion of neurons that were dopaminergic was determined by TH/TUJ1. Mean ± SEM of n = 2 or 3 clones per individual; 4 images per clone.(D) Immunofluorescent co-labelling of differentiated neuronal cultures from clone 3B fixed at DIV27 (1 week after re-plating) demonstrates expression of dopaminergic neuronal protein TH together with β3-tubulin. Scale bars, 50 μm. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Differentiation of iPSCs toward a midbrain fate generated dopaminergic neuronal cultures expressing neuron-specific beta-III tubulin (β3-tub) and the dopaminergic neuronal marker tyrosine hydroxylase (TH), identified by western blot ([Figure 1](#fig1){ref-type="fig"}B) and immunocytochemistry ([Figures 1](#fig1){ref-type="fig"}C and 1D). Approximately 65% of cells were β3-tub positive, with up to 60% of those co-expressing TH ([Figure 1](#fig1){ref-type="fig"}C).

Expression of the *MAPT* gene is both spatially and developmentally regulated, and it is primarily expressed in neurons. Adult human brain shows expression of six principal isoforms generated through the splicing of exons 2, 3, and 10 ([@bib2], [@bib13]), while the human fetus expresses only the shortest isoform, lacking exons 2, 3, and 10. To characterize the maturity of our dopaminergic neuronal cultures with respect to *MAPT* expression, we examined the expression of these isoforms over a 24-week (to 188 days *in vitro* \[DIV188\]) time course of maturation of iPSC-derived differentiation cultures using real-time qPCR. During this period the relative expression of total *MAPT* transcripts peaked at DIV48 (4 weeks after re-plating) ([Figure 2](#fig2){ref-type="fig"}A, see also [Figure S3](#mmc1){ref-type="supplementary-material"}B). By maturation to DIV188, cultures exhibited a 15-fold increase in the expression of adult isoforms containing exon 3 ([Figure 2](#fig2){ref-type="fig"}B) and a 7-fold increase in the expression of adult isoforms containing exon 10 ([Figure 2](#fig2){ref-type="fig"}C), both clear evidence of neuronal maturation. Cultures maintained in culture to DIV188 reached an inclusion level of exon 3 (encoding 2N tau protein isoforms) similar to levels in postmortem human midbrain (iPSC-derived cultures, 5.6%, [Figure 2](#fig2){ref-type="fig"}B; midbrain, 6.8%, [Figure 2](#fig2){ref-type="fig"}D). At the same time point, the inclusion of exon 10 (corresponding to the 4R tau protein isoforms) had risen toward the level of inclusion measured in postmortem human midbrain (iPSC-derived cultures, 18.2%, [Figure 2](#fig2){ref-type="fig"}C; compared with midbrain at 35.2%, [Figure 2](#fig2){ref-type="fig"}D).Figure 2*MAPT* Adult Isoforms Increase in Expression over a 6-Month Differentiation(A--C) Real-time qPCR analysis demonstrated changes in *MAPT* expression over 24 weeks of maturation to DIV188. Each graph shows mean ± SEM, n = 7 clones (all clones except 1A). At DIV188, peak mean inclusion for the alternatively spliced exons 3 and 10 was 5.6% (B) and 18.2% (C), respectively. For each graph (A--C), linear regression performed using all data points from DIV48 to DIV188 with an F test confirming that each slope is significantly different from zero: (A) y = −0.01303 × x + 0.7279, F = 4.615, p = 0.0391; (B) y = 0.2553 × x − 0.7078, F = 23.32, p \< 0.0001; (C) y = 0.7416 × x − 0.05151, F = 96.28, p \< 0.0001.(D) Exon inclusion from TaqMan-based real-time qPCR expression assays performed on human midbrain cDNA. Mean ± SEM, n = 5 individuals; exon 3+ mean = 6.79 ± 1.43; exon 10+ mean = 35.22 ± 2.43. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Dopaminergic neuronal cultures of all eight iPSC lines were matured for 6 months (DIV190) to give mature inclusion of adult-specific exons in *MAPT* transcripts. Western blot analysis of 6-month cultures revealed that the inclusion of exons 3 and 10 at the transcript level led to the presence of all six isoforms of tau protein, detected by either a pan-tau antibody or antibodies probing for 4R and 2N tau isoforms ([Figure 3](#fig3){ref-type="fig"}). Tau protein was not detected by the antibody Tau-1 in iPSCs before commencing differentiation ([Figure 3](#fig3){ref-type="fig"}, lanes 2--4). After running this blot, one particular batch of iPSC line 1A (lane 6) was discovered to have a duplication in chromosome 1q and was removed from further analysis. Overall, these data show that, by 6 months, iPSC-derived dopaminergic neuronal cultures show significant adult-like maturity, recapitulating expression patterns seen in adult midbrain, and represent a promising model for the study of *MAPT* biology.Figure 3All Major Tau Protein Isoforms Are Expressed in iPSC-Derived Dopaminergic Neuronal Cultures Differentiated for 6 MonthsWestern blots showing the presence of all six major isoforms of mature tau protein in dopaminergic neuronal cultures at DIV190, as detected by antibodies against total tau (Tau-1) or specific isoforms (4R Tau, 2N Tau). All samples dephosphorylated, except the right lane as an untreated control. 2N Tau blot: central bands indicated by blue arrows represent the two 2N Tau isoforms. Additional bands are considered non-specific as they appear in the iPSC lysate in which no tau is detectable.

Haplotype-Specific Expression of *MAPT* in Human Dopaminergic Neuronal Cultures {#sec2.2}
-------------------------------------------------------------------------------

We used our model to investigate the haplotype-specific expression of *MAPT* in dopamine neurons, the neuronal type that is preferentially vulnerable in PD. Samples from the same 6-month neuronal cultures of the eight heterozygous H1/H2 iPSC lines shown above were analyzed by real-time qPCR. The levels of total *MAPT* transcripts showed no significant difference between individuals ([Figure 4](#fig4){ref-type="fig"}A). Transcripts containing exon 3 also showed no significant difference between individuals, with the average inclusion of exon 3 for all eight lines being 9.1% ([Figure 4](#fig4){ref-type="fig"}B). However, individual 3 showed a significantly higher inclusion of exon 10 in *MAPT* transcripts (22%) compared with individuals 1 (16%) and 2 (15%) (p = 0.0005) ([Figure 4](#fig4){ref-type="fig"}B).Figure 4Dopaminergic Neuronal Cultures Exhibit Significant Differences in Isoform Expression from H1 and H2 Alleles at 6 MonthsTaqMan-based real-time qPCR expression assays on samples at DIV190. Mean ± SEM; individual 1, n = 1 clone; individuals 2 and 3, n = 3 clones; ≥3 cDNA samples per clone.(A) Total *MAPT* expression reported as relative ΔC~T~ of geometric mean of three housekeeper genes (*GAPDH, HPRT1,* and *ACTB*). n.s., not significant, one-way ANOVA.(B) Percent inclusion of alternatively spliced exons 3 (light blue) and 10 (dark blue) at DIV190. The three individuals show similar inclusion of exon 3, whereas individual 3 shows a significantly greater inclusion of exon 10. Significant difference between groups in an unpaired t test: ^∗∗∗^p = 0.0005.(C--E) Allele-specific expression assays distinguishing transcripts of H1 and H2 allelic origin, presented as H1:H2 ratio, i.e., values \>1 show higher H1 expression. Data from analysis of human midbrain (C) n = 9; (D) n = 5; and (E) n = 9. (C) Individuals 2 and 3 show significantly greater expression of total *MAPT* transcripts from the H1 chromosome (individual 2, ^∗∗^p = 0.0059; individual 3, ^∗^p = 0.0471; midbrain, n.s.). (D and E) The H1:H2 ratio is normalized to the H1:H2 ratio of total *MAPT* transcripts per sample. ^∗^Significant difference from mean of 1 in a one-sample t test. (D) There are 2-fold greater exon 3-containing transcripts coming from the H2 chromosome. Individual 2, ^∗∗^p = 0.0032; individual 3, ^∗∗^p = 0.0040; midbrain, ^∗∗^p = 0.0020. (E) Haplotype-specific expression of exon 10 varies between individuals and midbrain: Individual 2, n.s.; individual 3, ^∗∗∗^p = 0.0008; midbrain, ^∗∗^p = 0.0005. Significant difference between groups in an unpaired t test: ^∗∗∗^p = 0.0005. See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

The high levels of mature *MAPT* exons 3 and 10 inclusion allow the development of allele-specific expression assays to distinguish the relative abundance of H1 and H2 transcripts using a SNP. We developed a set of TaqMan-based real-time qPCR allele-specific expression assays using SNPs in exon 1 (rs17650901) and exon 9 (rs17652121) of *MAPT* to distinguish between transcripts deriving from H1 and H2 alleles ([Figure 4](#fig4){ref-type="fig"}, see also [Figures S3](#mmc1){ref-type="supplementary-material"}C--S3F). The output of these assays is the ratio of H1:H2 transcripts for a given PCR amplicon, in which a ratio greater than 1 represents more expression from the H1 allele than from the H2 allele, and a ratio less than 1 represents more expression from the H2 allele than from the H1 allele.

The expression of all *MAPT* transcripts combined, measured by amplifying transcripts between constitutive exons 0 and 1, was 23% greater from H1 than from H2 in DIV190 dopaminergic neuronal cultures ([Figure 4](#fig4){ref-type="fig"}C) (p \< 0.0001), with significantly greater H1 expression also seen at DIV124 (11%; p = 0.0132) and DIV188 (31%; p \< 0.0001) in the time course sample set ([Figure S4](#mmc1){ref-type="supplementary-material"}). In the same assay, total *MAPT* expression in postmortem human midbrain did not differ significantly from an allelic ratio of 1 ([Figure 4](#fig4){ref-type="fig"}C).

The average H1:H2 allelic ratio of *MAPT* transcripts containing exon 3 was 0.56 across all iPSC-derived dopaminergic culture sample sets, closely matching that of 0.51 in the midbrain sample set ([Figure 4](#fig4){ref-type="fig"}D, see also [Figure S4](#mmc1){ref-type="supplementary-material"}B). This demonstrates that the H2 allele expresses approximately twice as many *MAPT* transcripts containing exon 3 as the H1 allele. These exon 3 expression data from dopaminergic neuronal cultures and midbrain agree with those of postmortem brain tissue and other neuronal models studied previously ([@bib6], [@bib34]).

Finally, the allelic ratios of *MAPT* transcripts containing exon 10 were not different from 1 for DIV190 dopaminergic neuronal cultures from individuals 1 and 2 ([Figure 4](#fig4){ref-type="fig"}E). However, cultures from individual 3 showed a marked shift to a ratio of 0.51 ([Figure 4](#fig4){ref-type="fig"}E, see also [Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D), which we investigated further below. Consistent with previous observations in postmortem brain tissue and other neuronal models ([@bib5]), but differing from our iPSC-derived dopaminergic neuronal cultures, postmortem human midbrain exhibited an H1:H2 ratio for exon 10+ transcripts of 1.2 ([Figure 4](#fig4){ref-type="fig"}E).

In summary, our iPSC-derived dopaminergic neuronal culture model recapitulates the allele-specific expression differences previously seen in human brain for exon 3, exhibiting a 2-fold increase from H2. Although we observed an increased total *MAPT* expression associated with the H1 *MAPT* haplotype as reported previously ([@bib1], [@bib22]), we did not observe changes in exon 10+ expression associated with *MAPT* haplotype. Interestingly, our iPSC-derived neuronal cultures permitted the observation of a further expression phenotype in the iPSC lines from individual 3.

Identification of a Genetic Variant that Alters the Inclusion of *MAPT* Exon 10 {#sec2.3}
-------------------------------------------------------------------------------

We noted that the *MAPT* exon 10 expression in dopaminergic neuronal cultures from the three iPSC clones from individual 3 was significantly different to neurons studied from five lines generated from individuals 1 and 2. Dopaminergic neuronal cultures generated from individual 3 showed an overall 40% increase in inclusion of exon 10 ([Figure 4](#fig4){ref-type="fig"}B) and a 2-fold increase in expression of exon 10+ transcripts, specifically from the H2 allele ([Figure 4](#fig4){ref-type="fig"}E). To investigate these expression phenotypes further, *MAPT* exons 9 and 10 and their flanking regions were sequenced. Individuals 1 and 2 showed the expected wild-type (WT) sequence; however, an indel was detected in individual 3 that resulted in a divergent sequence 102 bp downstream of exon 10 ([Figure 5](#fig5){ref-type="fig"}A). Primers placed in or adjacent to the haplotype-tagging 238 bp indel in intron 9 were used to specify the allele to be amplified by PCR and each chromosomal locus was subcloned and sequenced. A deletion of three nucleotides was identified in intron 10 (c.1919+102_1919+104delCTT, hereafter ΔCTT) only in the H2 allele of individual 3 and not on either allele of in individuals 1 and 2 ([Figure 5](#fig5){ref-type="fig"}B). This ΔCTT variant does not exist on public databases of genetic variation ([www.ncbi.nlm.nih.gov/variation/view/](http://www.ncbi.nlm.nih.gov/variation/view/){#intref0010}), ([www.ncbi.nlm.nih.gov/SNP/](http://www.ncbi.nlm.nih.gov/SNP/){#intref0015}\[[@bib29]\]). As the deletion was present on the allele that showed increased exon 10 inclusion, this strongly suggests that the ΔCTT variant causes increased inclusion of exon 10 in agreement with the altered H1:H2 exon 10 inclusion ratio.Figure 5A Deletion in *MAPT* Intron 10 Decreases Binding of Factors that Regulate Exon 10 Splicing(A) Sequencing chromatograms for *MAPT* intron 10 showing the expected sequence for genomic DNA (both H1 and H2 alleles together) for individuals 1 and 2. The red x\'s represent divergent chromatograms from two overlapping sequences caused by an indel on one allele for individual 3.(B) Sequencing chromatograms for *MAPT* intron 10 showing single allelic genomic DNA from individual 3. The H2 allele showed a ΔCTT variation.(C) Electrophoretic mobility shift assay using an RNA probe for an intron 10 wild-type (WT) sequence (lanes 1--6) and an RNA probe for an intron 10 ΔCTT variant sequence (lanes 7--12), with and without competitors.(D) Western blot of RNA-protein pull-down using the WT and ΔCTT RNA probes. Lanes indicate proteins obtained from nuclear extract only (NE), beads only (B), NE and B (NEB), WT RNA probe and the ΔCTT probe. Blots are shown for PTPB1 and RMB4. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

To examine possible functional mechanisms for the increased inclusion of exon 10 in transcripts that include the ΔCTT variant, an *in silico* search of splice factor binding sites was performed on the intronic sequence with or without the ΔCTT variant using *SpliceAid 2* ([Figure 5](#fig5){ref-type="fig"}, see also [Figure S5](#mmc1){ref-type="supplementary-material"}) ([@bib26]). Searching for all available splicing factors, two binding sites were predicted to be lost by the ΔCTT variant: RBM4, which is predicted to enhance inclusion of exon 10 ([@bib19]), and PTBP1 (PTB/hnRNP I), which is predicted to promote exclusion of exon 10 ([@bib36]). In the presence of the ΔCTT variant, the predicted binding site for RBM4 would be reduced from 9 to 6 bp, and that of PTBP1 from 6 to only 3 bp. Real-time qPCR for *RBM4* and *PTBP1* confirmed the expression of both of these splicing factors in cultures of clones from each of the three individuals across the period of the time course ([Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D). Furthermore, the expression of *RBM4* and *PTBP1* appears to be correlated in these samples ([Figure S5](#mmc1){ref-type="supplementary-material"}E). From DIV48, the expression levels of both genes appears to be relatively stable, rather than matching the observed increase in inclusion of exon 10 over time. Importantly, although there was a clear difference in *MAPT* exon 10 inclusion between individual 3 and individuals 1 and 2 ([Figure S5](#mmc1){ref-type="supplementary-material"}F), there was no difference in the expression of *RBM4* and *PTBP1* in the clone from individual 3 when compared with clones from individuals 1 and 2, showing that there is no intrinsic difference in the expression of these splicing factors that could otherwise explain the phenotype of individual 3.

We performed RNA-electrophoretic mobility shift assays to study the impact of the ΔCTT sequence on RNA-protein complex formation between biotinylated RNA probes containing the exon 10 WT or ΔCTT sequence and SK-N-F1 nuclear protein extract ([Figure 5](#fig5){ref-type="fig"}C). Four RNA-protein complexes (I--IV) were formed using the WT RNA probe ([Figure 5](#fig5){ref-type="fig"}C, lane 2), while only three (II--IV) were visible when the CTT sequence was deleted ([Figure 5](#fig5){ref-type="fig"}C, lane 8), indicating that the CTT deletion reduced the number of species of protein complexes interacting with the RNA. The band shift intensities of the WT sequence and nuclear extract were much stronger than those observed for the ΔCTT sequence ([Figure 5](#fig5){ref-type="fig"}C, lanes 2 and 8), suggesting that the CTT sequence forms part of an important RNA motif for protein binding. We further assessed the binding strengths of the WT and ΔCTT sequences by competition experiments in which unlabeled RNA oligonucleotides competed with the probes for complex formation ([Figure 5](#fig5){ref-type="fig"}C, lanes 3--6, 9--12). The ΔCTT competitor showed a reduced competition strength compared with the WT competitor when assayed with the WT probe for complex formation ([Figure 5](#fig5){ref-type="fig"}C, lanes 3--6), whereas the two competitor oligonucleotide sequences exhibited comparable competition strength with the ΔCTT probe ([Figure 5](#fig5){ref-type="fig"}C, lanes 9--12).

We probed for interaction of PTBP1 and RBM4 after pull-down of nuclear proteins with the WT or ΔCTT probes ([Figure 5](#fig5){ref-type="fig"}D). Firstly, this technique successfully shows an interaction of PTPB1 with both probes, whereas the signal for RBM4 rose barely above background despite robust presence in the starting lysate. Secondly, the PTBP1 interaction with the ΔCTT variant is greatly reduced compared with the WT sequence. The results indicate that a CTT deletion in this region could potentially reduce the binding of RNA binding proteins such as PTPB1, thereby altering the balance of exon 10 inclusion and exclusion in transcripts.

Tau Knockdown Alters Velocity of Axonal Transport in Human Dopaminergic Neuronal Cultures {#sec2.4}
-----------------------------------------------------------------------------------------

The *MAPT* H1 allele is established to carry risk for PD, and we describe above an increased allelic expression of total *MAPT* transcripts in dopaminergic neuronal cultures compared with the protective H2 allele ([Figure 4](#fig4){ref-type="fig"}C). Furthermore, our postmortem human midbrain samples confirmed increased expression of exon 10+ *MAPT* transcripts from the H1 allele ([Figure 4](#fig4){ref-type="fig"}E). We note that both of these scenarios would contribute to having more molecules of 4R tau protein present in cells carrying the H1 allele. We therefore developed a dual approach to investigate the functional effect of 4R tau expression in dopaminergic neuronal cultures. We hypothesized that a decrease in the level of total tau expression, or 4R tau expression, both of which mimic the protective H2 condition, may be beneficial to dopamine neurons. We designed short hairpin RNAs (shRNAs) to target either a constitutive exon of *MAPT* (i.e., all transcripts), or targeted specifically at *MAPT* transcripts including exon 10, or a scrambled shRNA not matching any known RefSeq transcript. These three shRNA sequences were incorporated into lentiviral plasmids. Following transduction at DIV20 shortly after re-plating, dopaminergic neuronal cultures were matured for either 4 weeks or 5 months. Tau protein was knocked down by 65% at 4 weeks ([Figure 6](#fig6){ref-type="fig"}A), with knockdown persisting at 5 months post-transduction ([Figure 6](#fig6){ref-type="fig"}B), while maintaining expression of the blue fluorescent protein (EBFP2) reporter ([Figure 6](#fig6){ref-type="fig"}C). The shRNA targeting *MAPT* exon 10 efficiently knocked down 4R tau protein in 5-month cultures ([Figure 6](#fig6){ref-type="fig"}B). Cultures were incubated with MitoTracker Deep Red to enable visualization of mitochondria for live fluorescence imaging ([Figure 6](#fig6){ref-type="fig"}D). After using the EBFP2 reporter to identify transduced neurons, analysis of kymographs generated from time-lapse imaging enabled measurement of the velocity of mitochondria ([Figure 6](#fig6){ref-type="fig"}E).Figure 6Knockdown of 4R Tau Increases Velocity of Mitochondrial Axonal Transport in iPSC-Derived Dopaminergic Neuronal Cultures Differentiated for 5 Months(A) Western blots showing knockdown of tau protein in dopaminergic neuronal cultures 4 weeks post-transduction. ^∗^p = 0.0457.(B) Western blots after protein dephosphorylation show knockdown of tau protein and 4R tau isoforms persisting in 5-month dopaminergic neuronal cultures with β-actin loading control.(C) Fluorescence microscopy image of EBFP2 expression during axonal transport live imaging at 5 months. Scale bar, 25 μm.(D) Selected time-lapse fluorescence microscopy images of axonal mitochondria in dopaminergic neuronal cultures stained with MitoTracker Deep Red. Arrowheads show motile mitochondria.(E) Kymograph time-space plot of a trace along the linear path of an axon, from which mitochondrial motility parameters can be determined.(F) Cumulative frequency graphs of average mitochondrial velocity in dopaminergic neuronal cultures at (top) 4 weeks post-transduction and (bottom) 5 months post-transduction. (Left) Average total velocity of each measured motile mitochondrion; (right) average velocity of each measured motile mitochondrion after removal of time when paused. All four graphs were statistically significant in Kruskall-Wallis nonparametric tests: upper left, p = 0.0033; upper right, p = 0.0200; lower left, p \< 0.0001; lower right, p \< 0.0001. ^∗^Significance in the follow-up Dunn\'s multiple comparisons test (nonparametric) compared with scrambled shRNA control: ^∗^p \< 0.05; ^∗∗∗^p \< 0.001. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

When compared with the scrambled shRNA control, there was no significant difference in mitochondrial velocity when tau protein was reduced in young neurons (4 weeks post-transduction; [Figure 6](#fig6){ref-type="fig"}F, upper). However, in older neurons (5 months post-transduction) where the complement of tau proteins is more representative of expression in the adult human brain, knockdown by the 4R *MAPT* shRNA caused a significant increase in median mitochondrial velocity from 0.148 to 0.574 μm/s (adjusted p = 0.0007; [Figure 6](#fig6){ref-type="fig"}F, lower left). Furthermore, when the period during which a mitochondrion has paused is removed from the calculations for average velocity, both knockdown conditions (4R and total *MAPT*) produced a significant increase in median mitochondrial velocity compared with the scrambled shRNA control, from 0.272 μm/s for scrambled to 0.793 and 0.519 μm/s for 4R and total *MAPT* knockdown, respectively (4R *MAPT* adjusted p = 0.0002; total *MAPT* adjusted p = 0.0191; [Figure 6](#fig6){ref-type="fig"}F, lower right). As the level of total tau protein is similar between the two knockdown conditions, these data suggest that the disruption of the balance of 4R and 3R tau isoforms is what is giving rise to the most significant differences in mitochondrial velocity. This increase remains, and is reinforced, after removal of pause periods, suggesting that the alteration in velocity is not simply due to a reduction in the chance of a mitochondrion stalling/pausing, but to an intrinsic increase in the velocity of axonal transport.

Due to the requirement for high-density cultures to generate TH+ dopaminergic neurons, it was not possible to determine transport direction in our assay system as axons were not able to be assigned to specific cell bodies. Kinesin produces movement solely in the anterograde direction, whereas cytoplasmic dynein, while predominantly a retrograde motor, is capable of reversing and so functions bidirectionally ([@bib10]), so we therefore stratified the data by separating mitochondria that had \>90% of their movement in a single direction (unidirectional) from those that were bidirectional. In young neurons, no significant difference was observed between knockdown and scrambled conditions. In older neurons, knockdown of 4R tau resulted in a significant increase in velocity for mitochondria moving in one direction only, with or without inclusion of paused periods ([Figure S6](#mmc1){ref-type="supplementary-material"}E: p = 0.0048; [Figure S6](#mmc1){ref-type="supplementary-material"}F, p = 0.0033), but showed no difference in velocity of bidirectional mitochondria ([Figures S6](#mmc1){ref-type="supplementary-material"}G and S6H), showing that the overall effect seen by 4R tau knockdown was carried by unidirectional mitochondria. In contrast, knockdown of total tau resulted in increased velocity of both unidirectional and bidirectional mitochondria, but only when pause periods were removed ([Figure S6](#mmc1){ref-type="supplementary-material"}F, p = 0.0078; [Figure S6](#mmc1){ref-type="supplementary-material"}H p = 0.0327). These data suggest tau regulates kinesin anterograde transport to a greater extent than dynein anterograde transport.

Discussion {#sec3}
==========

In this work, we have established an iPSC-derived dopaminergic neuronal cell culture model suitable for the study of the expression and function of *MAPT* in those neurons preferentially vulnerable to neurodegeneration in PD. We have shown that iPSC-derived dopaminergic neuronal cultures expressing a high level of the neuronal markers β3-tub and TH show increasing expression of adult tau isoforms throughout the maturation phase. Notably, levels of expression of exon 3+ and exon 10+ transcripts approach adult levels after 6 months of neuronal maturation, with strong expression of 2N and 4R tau protein isoforms evident. This highly physiological *MAPT* expression profile makes iPSC-derived dopaminergic neurons a highly suitable system to study the genetic regulation of tau expression in a tractable human dopamine neuronal culture model.

An important aspect of tau biology is the effect of *MAPT* genetic variation on the expression of tau isoforms. Discovery of exon 10 splice site mutations in pedigrees with FTDP-17 demonstrated for the first time that *MAPT* non-coding genetic variation changed the balanced expression of the 3R and 4R tau protein, and that the imbalanced expression was sufficient to cause disease ([@bib17], [@bib31]). Studies by our group ([@bib5], [@bib6]) and others ([@bib23], [@bib34]) have demonstrated that common *MAPT* genetic variation associated with disease alters the expression of tau transcripts and that this effect varies between brain regions. Combining these attributes of tau biology requires tau to be studied in a tractable model expressing the adult tau isoforms, such as iPSC-derived dopaminergic neuronal cultures.

Within the field of stem cell models of neurodegeneration, the age and maturity of iPSC-derived neuronal cultures is central to developing better models to study disease. *MAPT* isoform expression is developmentally regulated and therefore gives an excellent genetic marker of neuronal maturity. iPSC-derived dopaminergic neuronal cultures differentiated and matured using the protocol that we use here ([@bib21]) show increasingly more adult tau isoform expression over a maturation period of 6 months, with full-length 2N4R tau protein being detected at DIV190. Other studies of dopaminergic cultures detected mostly fetal tau present after 20 days in maturation medium ([@bib11]), which is in line with our findings. Similar expression patterns are noted in iPSC-derived cortical neuronal cultures. A detailed examination of tau proteins by mass spectrometry provided confirmation of the predominance of 0N3R tau peptides and the lack of peptides corresponding to exons 2 and 3 in 5-week iPSC-derived cortical neurons ([@bib30]). Wray and colleagues ([@bib32]) noted that their iPSC-derived cortical cultures go through the developmental switch from fetal to adult tau after 365 days. Alteration of the developmental switch to adult tau isoforms occurs in cultures with tau mutations in which increased expression of 4R tau is observed at earlier time points than control ([@bib11], [@bib18], [@bib30], [@bib32]). Despite differences in cortical and dopaminergic differentiation protocols, it is clear that the expression of the adult isoforms of tau requires extended periods of maturation. This is perhaps unsurprising considering the natural developmental switch of expression from fetal tau to adult tau over time in the human brain. As the tau isoform balance has proven key to the pathogenicity of splice site mutations in FTDP-17, and is a characteristic of the genetic association, the expression of the adult isoforms in neuronal cell culture models is vitally important for future tau biology work.

Our differentiated neuronal cultures allow us to investigate the effect of common genetic variation on *MAPT* expression. The allele-specific expression assays we developed detect differences in expression from the H1 and H2 haplotypes within heterozygous lines. We demonstrate that the dopaminergic neuronal cultures express 22% greater tau transcripts from the H1 chromosome than H2. This allelic difference in total tau expression has not been demonstrated in studies of postmortem tissue ([@bib5], [@bib34]), although other groups have reported it using genetic reporter constructs ([@bib22]). Whether this difference would change with even longer maturation phases is as yet unclear; however, we observe an increasing H1:H2 total tau over our time course. Interestingly, [@bib15] noted a negative correlation between H1:H2 total transcript ratio and age, indicating that age-related changes in haplotype expression are relevant in the human brain. When we examine the alternatively spliced *MAPT* transcripts at 6 months maturation, neurons possess a mature expression profile, recapitulating the 2-fold greater exon 3 containing transcripts from the H2 chromosome correctly mirroring expression in midbrain and other postmortem tissue regions ([@bib6], [@bib34]).

Our iPSC-derived dopamine neuronal cultures express exon 10 from the H1 and H2 chromosomes at equal ratio which differs from the ratio observed here in the midbrain tissue, as well as in previous publications of postmortem brain tissue ([@bib5], [@bib23]). It is possible this discrepancy arises due to the maturity or age of the culture as we document an increase in the expression of tau isoforms over extended maturation phases, although inclusion does not reach the 35% level seen in the midbrain samples. While the exon 10-containing transcripts maintain a similar H1:H2 transcript ratio throughout, it is possible that the ratios could change as exon 10 inclusion approaches the level of the adult midbrain. Alternatively, while this iPSC-derived model of dopaminergic neurons cultures provides a system in which to assay the function of the adult tau isoforms, it is possible that the culture system here may not support all the factors to recapitulate exon 10 inclusion as seen in the brain, which in turn would explain why the adult levels of exon 10 expression have not been achieved.

In our study we identified a rare non-coding variant within the *MAPT* locus. The previously undescribed ΔCTT variant occurring within intron 10 was found to alter the inclusion of exon 10 in transcripts and to change the balance of 4R tau protein isoforms. We observed a greater number of protein complexes bound the WT sequence than the ΔCTT variant, which agrees with in silico analysis predictions of the loss of two binding sites for RBM4 and PTBP1. We suggest that a partial loss of binding of RBM4 and a near abrogation of binding of PTBP1 would increase the likelihood of inclusion of exon 10 in transcripts originating from the ΔCTT H2 allele; alternatively, the loss of binding of both factors could alter the balance of remaining factors to promote exon 10 inclusion. The ability to assay the effect of genetic variation at the expression level is the first step in studying a range of tauopathies, from diseases caused by specific tau mutations such as those found in FTDP-17, to diseases with strong genetic associations with *MAPT* as in PD, PSP, and CBD.

It is clear from work on FTDP-17 splice site mutations ([@bib17], [@bib31]), as well as investigations into haplotype-specific expression of tau isoforms ([@bib5], [@bib6], [@bib34]), that the balance of tau isoform expression plays a major role in disease; however, the functional impact of subtle changes in expression brought about by common variants has yet to be fully investigated. The importance of the expression of alternative tau isoforms in the study of axonal transport was previously suggested by a study investigating the regulation of dynein and kinesin motor proteins. The longest tau isoform (2N4R) was shown to be a less potent inhibitor of both kinesin and dynein than the shortest tau isoform (0N3R) ([@bib10]). The high levels of adult tau isoform expression in our differentiated neuronal cultures allows us to investigate the effect of tau isoform expression on neuronal function. We have shown that depletion of 4R tau isoforms leads to increased axonal transport velocity in 5-month-old dopaminergic neuronal cultures. As this effect is strengthened after removal of pause periods it is likely that the alteration in velocity is not simply due to a reduction in the chance of a mitochondrion stalling/pausing, but to an intrinsic increase in the velocity of axonal transport. In addition, the effect of knockdown was greatest in mitochondria with unidirectional movement, which may support the data that indicate that tau affects kinesin anterograde movement greater than dynein ([@bib10]). We propose that the H2 haplotype, which expresses reduced 4R tau compared with the H1 haplotype, may exert a protective effect as it allows for more fluid mitochondrial movement along axons with high energy requirements, such as the dopaminergic neurons that degenerate in PD.

Advances in iPSC-derived neuronal models have opened up a new frontier for the study of human neurons as highly relevant genetic models, capturing the variants present in the donor. iPSC-derived dopaminergic neuronal cultures are known to be of high neurophysiological relevance ([@bib14]) and reveal cellular phenotypes when comparing patients and controls ([@bib12]) suitable for target and drug discovery. Here, we have been able to exploit iPSC-derived neurons to model the genetic basis of susceptibly to common disease by specifically choosing certain genotypes to functionally determine the effect of genetic variants on cell biology in the specific cell type of interest. Together, these attributes of iPSC-derived neuronal models demonstrate the great potential of studying neurons in a dish for future investigation into the genetic basis of neurodegenerative disorders.

Experimental Procedures {#sec4}
=======================

iPSCs {#sec4.1}
-----

All iPSC lines were derived from dermal fibroblasts from disease-free donors recruited through the Oxford Parkinson\'s Disease Center: participants were recruited to this study having given signed informed consent, which included derivation of hiPSC lines from skin biopsies (Ethics Committee: National Health Service, Health Research Authority, NRES Committee South Central, Berkshire, UK, who specifically approved this part of the study \[REC 10/H0505/71\]). All iPSC lines are detailed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}, [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}; [Table S1](#mmc1){ref-type="supplementary-material"}.

Differentiation of iPSCs to Dopaminergic Neuronal Cultures {#sec4.2}
----------------------------------------------------------

iPSCs were differentiated into dopaminergic neuronal cultures according to a modified protocol of [@bib21] (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}). The medium was half changed every 2--3 days for the extended periods of maturation up to DIV190.

Allele-Specific Real-Time qPCR {#sec4.3}
------------------------------

Pairs of TaqMan probes were identified to distinguish the H1 and H2 alleles at *MAPT* SNP1 (rs17650901) and SNP9ii (rs17652121) [@bib24], and ordered as custom probe-only assays from Applied Biosystems. Validation of specificity was performed using H1/H1 or H2/H2 genomic DNA, followed by the generation of standard curves from 8:1 to 1:8 with *MAPT* H1 and H2 BAC constructs ([Figure S3](#mmc1){ref-type="supplementary-material"}), which were adjusted through the origin.

Mitochondrial Axonal Transport Imaging {#sec4.4}
--------------------------------------

Cultures of iPSC-derived dopaminergic neuronal cultures were transduced with lentiviral particles encoding shRNAs on DIV20. Cultures were maintained until 4 weeks post re-plating or 5 months post re-plating before imaging. Cultures were incubated with MitoTracker Deep Red (Invitrogen) for 30 min then washed with Hank's balanced salt solution with calcium and magnesium. Time-lapse imaging with Cy5 channel was performed using Volocity software to generate 150 images at 1-s intervals with 110-ms exposure ([@bib35]). Single EBFP2 images were taken on the DAPI channel to identify transduced neurons for each video.

Statistical Analysis {#sec4.5}
--------------------

All statistical analysis and graphical representation was performed in Prism version 7 (GraphPad software). Specific tests are noted in each figure legend. For allele-specific expression studies, two-tailed one-sample t tests were used to determine whether the mean H1:H2 ratio was significantly different from 1. Unpaired two-tailed t tests were used to compare the expression levels of two groups. For axonal transport data, motile mitochondria from multiple imaging sessions were combined to produce a cumulative frequency (%) plot and analyzed by Kruskall-Wallis test with Dunn\'s multiple-testing correction. Knockdown conditions were compared with non-targeted shRNA conditions.
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